BC Extra | Aug 9, 2019
Preclinical News

Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

Mayo Clinic liquid biopsy identifies breast cancer residual disease  A Mayo Clinic team reported in a Science Translational Medicine article that a personalized multiplex sequencing approach called TARDIS (targeted digital sequencing) could accurately distinguish pathological...
BC Week In Review | Jul 20, 2018
Clinical News

CytoDyn reports 25-week Phase IIb/III data for HIV candidate

CytoDyn Inc. (OTCBB:CYDY) reported 25-week data from the double-blind, U.S. Phase IIb/III CD02 trial of PRO 140 in 52 patients with HIV infection who were failing their current HIV therapy and reiterated its plan to...
BC Week In Review | Mar 2, 2018
Clinical News

CytoDyn's PRO 140 meets in Phase IIb/III for HIV infection

CytoDyn Inc. (OTCBB:CYDY) reported data from the double-blind, U.S. Phase IIb/III CD02 trial in 52 patients with HIV infection who were failing their current HIV therapy showing that a 350 mg subcutaneous injection of PRO...
BC Innovations | Jan 8, 2018
Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest CCR5 inhibitors could help treat osteoporosis. In a mouse model of osteoporosis, systemic knockout of CCR5 decreased trabecular bone loss in the femur compared with normal expression. Next steps could...
BC Innovations | Nov 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
BC Week In Review | Jun 9, 2017
Clinical News

CytoDyn starts Phase II of PRO 140 to treat GvHD

CytoDyn Inc. (OTCQB:CYDY) began a Phase II trial of PRO 140 to prevent acute graft-versus-host disease (GvHD) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem cell transplant (ASCT). The...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Dec 13, 2016
Clinical News

PRO 140: Ph IIb/III started

CytoDyn began an open-label, U.S. Phase IIb/III trial to evaluate 350 mg subcutaneous PRO 140 once weekly as monotherapy for 48 weeks in about 300 patients with CCR5-tropic HIV-1 infection who are clinically stable on...
BC Week In Review | Oct 17, 2016
Clinical News

PRO 140: Phase III ongoing

FDA approved amendments to a double-blind, placebo-controlled, U.S. Phase III trial evaluating 350 mg subcutaneous PRO 140 once weekly plus standard of care antiretroviral therapy (ART) in treatment-experienced HIV-infected patients who are failing their ART...
BC Week In Review | Aug 8, 2016
Clinical News

PRO 140: Phase III started

CytoDyn began a modified, double-blind, placebo-controlled, U.S. Phase III trial to evaluate 350 mg subcutaneous PRO 140 once weekly plus standard of care antiretroviral therapy (ART) in treatment-experienced HIV-infected patients who are failing their ART...
Items per page:
1 - 10 of 61